These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31839085)

  • 1. Amino Acid Mutations in NS5B Protein among Treatment-naive Genotype 3A Infected Patients.
    Gul A; Ali I; Gul N; Ahmed J
    J Coll Physicians Surg Pak; 2019 Dec; 29(12):1149-1152. PubMed ID: 31839085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.
    Costantino A; Spada E; Equestre M; Bruni R; Tritarelli E; Coppola N; Sagnelli C; Sagnelli E; Ciccaglione AR
    Virol J; 2015 Nov; 12():186. PubMed ID: 26577836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates.
    Jaspe RC; Sulbarán YF; Sulbarán MZ; Loureiro CL; Rangel HR; Pujol FH
    Virol J; 2012 Sep; 9():214. PubMed ID: 22995142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of Hepatitis C virus 3a in Peshawar.
    Gul A; Zahid N; Ahmed J; Zahir F; Khan IA; Ali I
    BMC Infect Dis; 2016 Apr; 16():163. PubMed ID: 27090517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy.
    Karbalaie Niya MH; Salman-Tabar S; Bokharaei-Salim F; Behmanesh M; Keyvani H
    Microb Pathog; 2017 Apr; 105():166-170. PubMed ID: 28161357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients.
    Younas S; Sumrin A; Hussain N; Bilal M
    J Appl Microbiol; 2022 Nov; 133(5):2826-2834. PubMed ID: 35916643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
    Alves R; Queiroz AT; Pessoa MG; da Silva EF; Mazo DF; Carrilho FJ; Carvalho-Filho RJ; de Carvalho IM
    J Viral Hepat; 2013 Jun; 20(6):414-21. PubMed ID: 23647958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.
    Ahmed HR; Waly NGFM; Abd El-Baky RM; Yahia R; Hetta HF; Elsayed AM; Ibrahem RA
    PLoS One; 2021; 16(4):e0249770. PubMed ID: 33857212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women.
    Dryer PD; Limketkai BN; Martin CM; Ma G; Sherman KE; Taylor LE; Mayer KH; Jamieson DJ; Blackard JT
    J Antimicrob Chemother; 2009 Nov; 64(5):945-8. PubMed ID: 19767319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.
    Hedskog C; Dvory-Sobol H; Gontcharova V; Martin R; Ouyang W; Han B; Gane EJ; Brainard D; Hyland RH; Miller MD; Mo H; Svarovskaia E
    J Viral Hepat; 2015 Nov; 22(11):871-81. PubMed ID: 25784085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.
    Sede MM; Laufer NL; Quarleri J
    Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
    Ullah S; Rehman HU; Idrees M
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1146-51. PubMed ID: 23611896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.
    Gaudieri S; Rauch A; Pfafferott K; Barnes E; Cheng W; McCaughan G; Shackel N; Jeffrey GP; Mollison L; Baker R; Furrer H; Günthard HF; Freitas E; Humphreys I; Klenerman P; Mallal S; James I; Roberts S; Nolan D; Lucas M
    Hepatology; 2009 Apr; 49(4):1069-82. PubMed ID: 19263475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa.
    Prabdial-Sing N; Blackard JT; Puren AJ; Mahomed A; Abuelhassan W; Mahlangu J; Vermeulen M; Bowyer SM
    Antiviral Res; 2016 Mar; 127():90-8. PubMed ID: 26704023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina.
    Martínez AP; García G; Ridruejo E; Culasso AC; Pérez PS; Pereson MJ; Neukam K; Flichman D; Di Lello FA
    J Med Virol; 2019 Nov; 91(11):1970-1978. PubMed ID: 31273794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of the NS5B S282T mutation in HCV isolates from liver tissue of treatment-naive patients with HCV genotype-1b infection.
    Maimone S; Tripodi G; Musolino C; Cacciola I; Pollicino T; Raimondo G
    Antivir Ther; 2015; 20(2):245-7. PubMed ID: 25171743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy.
    Sugihara K; Orito E; Tanaka Y; Kato T; Lau JY; Ohno T; Hayashi K; Ogino M; Hirashima N; Sakakibara K; Mizuno Y; Kato H; Suzuki S; Ueda R; Mizokami M
    Intervirology; 2006; 49(6):319-26. PubMed ID: 16926544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
    Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
    Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a.
    Kiattanaphon A; Vipsoongnern Y; Kunthalert D; Sistayanarain A
    Mol Biol Rep; 2022 Oct; 49(10):9437-9443. PubMed ID: 36002650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.